The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Total neoadjuvant therapy has been increasingly adopted for multimodal rectal cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy needs to be established. OBJECTIVE: To report the long-term results of the secondary end points prespecified in the Randomized Phase 2 Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy (CAO/ARO/AIO-12 trial) for Locally Advanced Rectal Cancer. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a randomized clinical trial included 311 patients who were recruited from the accrued CAO/ARO/AIO-12 trial population from June 15, 2015, to January 31, 2018, from 18 centers in Germany. Patients with cT3-4 and/or node-positive rectal adenocarcinoma were included in the analysis. Data were analyzed from June 15, 2015, to January 31, 2018. The follow-up analysis was conducted between January 31, 2018, and November 30, 2020. INTERVENTIONS: Patients were randomly assigned to group A for 3 cycles of fluorouracil, leucovorin, and oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy), or to group B for CRT before chemotherapy. Total mesorectal excision was scheduled on day 123 after the start of total neoadjuvant therapy in both groups. MAIN OUTCOMES AND MEASURES: The end points assessed in this secondary analysis included long-term oncologic outcomes, chronic toxicity, patient-reported outcome measures for global health status (GHS) and quality of life (QoL), and the Wexner stool incontinence score. RESULTS: Of the 311 patients enrolled, 306 were evaluable, including 156 in group A (mean [SD] age, 60 [11] years; 106 men [68%]) and 150 in group B (mean [SD] age, 62 [10] years; 100 men [67%]). After a median follow-up of 43 months (range, 35-60 months), the 3-year disease-free survival was 73% in both groups (hazard ratio, 0.95; 95% CI, 0.63-1.45, P = .82); the 3-year cumulative incidence of locoregional recurrence (6% vs 5%, P = .67) and distant metastases (18% vs 16%, P = .52) were not significantly different. Chronic toxicity grade 3 to 4 occurred in 10 of 85 patients (11.8%) in group A and 8 of 66 patients (9.9%) in group B at 3 years. The GHS/QoL score decreased after total mesorectal excision but returned to pretreatment levels 1 year after randomization with no difference between the groups. Stool incontinence deteriorated 1 year after randomization in both groups and only improved slightly at 3 years, but never reached baseline levels. CONCLUSIONS AND RELEVANCE: This secondary analysis of a randomized clinical trial showed that CRT followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, QoL, or stool incontinence and is thus proposed as the preferred total neoadjuvant therapy sequence if organ preservation is a priority. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02363374.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,018
Etiology and management of fecal incontinence
Jorge, M. J. N., & Wexner, S. D. (1993) · Diseases of the Colon & Rectum · doi:10.1007/bf02050307 · Cited by 2,985
Bahadoer, R. R., Dijkstra, E. A., van Etten, B., Marijnen, C. A. M., Putter, H., Kranenbarg, E. M.-K., Roodvoets, A. G. H., Nagtegaal, I. D., Beets-Tan, R. G. H., Blomqvist, L. K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30555-6 · Cited by 1,693
Conroy, T., Bosset, J.-F., Etienne, P.-L., Rio, E., François, É., Mesgouez-Nebout, N., Vendrely, V., Artignan, X., Bouché, O., Gargot, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00079-6 · Cited by 1,344
Rödel, C., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R.-D., Ghadimi, M., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 726
Self-citationRödel, C., Liersch, T., Becker, H., Fietkau, R., Hohenberger, W., Hothorn, T., Graeven, U., Arnold, D., Lang-Welzenbach, M., Raab, H.-R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70187-0 · Cited by 696
Self-citationAdoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Cercek, A., Roxburgh, C. S. D., Strombom, P., Smith, J. J., Temple, L. K. F., Nash, G. M., Guillem, J. G., Paty, P. B., Yaeger, R., Stadler, Z. K., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0071 · Cited by 650
Fokas, E., Allgäuer, M., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00308 · Cited by 549
Self-citationBujko, K., Wyrwicz, L., Rutkowski, A., Malinowska, M., Pietrzak, L., Kryński, J., Michalski, W., Olędzki, J., Kuśnierz, J., Zając, L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw062 · Cited by 439
Fernández-Martos, C., Pericay, C., Aparicio, J., Salud, A., Safont, M., Massuti, B., Vera, R., Escudero, P., Maurel, J., Marcuello, E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8541 · Cited by 438
Metadata
- Authors
- Fokas, E., Schlenska-Lange, A., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., Kirste, S., Jacobasch, L., Allgäuer, M., Flentje, M., Germer, C.-T., Grützmann, R., Hildebrandt, G., Schwarzbach, M., Bechstein, W. O., Sülberg, H., Friede, T., Gaedcke, J., Ghadimi, M., Hofheinz, R.-D., Rödel, C., German Rectal Cancer Study Group, Imhoff, D., Woeste, G., Habbe, N., Pession, U., Hansmann, M.-L., Wild, P., Falk, S., Hödl, P., Serebrennikov, A., Schmeck, S., Paolucci, V., Sahm, S., Eichel, M., Römer, G., Bank, W., Moosmann, N., Braess, J., Piso, P., Wiesinger, H., Kappl, P., Germer, E., Warmuth-Metz, M., Kunzmann, V., Krajinovic, K., Rosenwald, A., Bley, T., Stölzel, U., Dörne, M., Renziehausen, L., Boese-Land, J., Meißner, D., Burchert, D., Dirsch, O., Habeck, J. O., Kirchhof, K., Lamberti, C., Leibl, B., Gschwendtner, A., Lahmer, G., Lang-Welzenbach, M., Hohenberger, W., Kuhnt, T., Papsdorf, K., Wittekind, C., Volkheimer, C., Wenz, F., Merx, K., Post, S., Gaiser, T., Attenberger, U., Geißler, M., Sträter, J., Gnann, H., Krämer, S., Henke, M., Schäfer, H., Manegold, P., Neeff, H. P., Bronsert, P., Schmiegel, W., Pohl, M., Möllecken, C., Adamietz, I., Viehbahn, R., Tannapfel, A., Freiberg-Richter, J., Jacobi, T., Wendt, W., Holzweißig, K., Kittner, T., Graeven, U., Lange, C., Kania, U., Rösler, E., Ortloff, H., Müller-Leisse, C., Folprecht, G., Ubbelohde, U., Baretton, G., Kölbl, O., Steger, F., Hofstädter, F., Schlitt, H. J., Stroszczynski, C., Binnebösel, M., Eble, M. J., Lüdde, T., Knüchel-Clarke, R., Bruners, P., Küchenmeister, U., Klar, E., Erbesdolber, A., Halm, U., Zachäus, M., Schneider, E., Schmidt, T., Köhne, C.-H., Rosin, B., Willborn, K. C., Henke, R.-P., Griesinger, F., & Flach, H.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2022-01-20
- Volume
- 8
- Issue
- 1
- Pages
- e215445
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3211715598
- Cited by
- 360
- References
- 22
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2021.5445
- The paper
- Fokas, E., Schlenska-Lange, A., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., Kirste, S., Jacobasch, L., Allgäuer, M., Flentje, M., Germer, C.-T., Grützmann, R., Hildebrandt, G., Schwarzbach, M., Bechstein, W. O., . . . Flach, H. (2022). Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2021.5445
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.